Winston Pharmaceutcl (WPHM) 0.0180 $WPHM Cancer Pain

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Winston Pharmaceutcl (WPHM) 0.0180 $WPHM

Cancer Pain Pipeline Review, H2 2015
M2 - Fri Feb 05, 4:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/3tjd78/cancer_pain) has announced the addition of the "Cancer Pain - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cancer Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Cancer Pain Overview - Therapeutics Development - Pipeline Products for Cancer Pain - Overview - Pipeline Products for Cancer Pain - Comparative Analysis - Cancer Pain - Therapeutics under Development by Companies - Cancer Pain - Therapeutics under Investigation by Universities/Institutes - Cancer Pain - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Cancer Pain - Products under Development by Companies - Cancer Pain - Products under Investigation by Universities/Institutes - Cancer Pain - Companies Involved in Therapeutics Development - Amgen Inc. - Amorsa Therapeutics Inc. - AngioChem Inc. - Aphios Corporation - AstraZeneca Plc - BCN Peptides, S.A. - Benitec Biopharma Limited - BioDelivery Sciences International, Inc. - ChironWells GmbH - Daiichi Sankyo Company, Limited - Fujimoto Pharmaceutical Corporation - Grunenthal GmbH - GW Pharmaceuticals Plc - Hisamitsu Pharmaceutical Co., Inc. - Immupharma Plc - IntelGenx Corp. - Kolon Life Science, Inc. - Nektar Therapeutics - Neurocentrx Pharma Ltd. - Orion Oyj - Pain Therapeutics, Inc. - Pfizer Inc. - Pharmaleads - PsychoGenics, Inc. - Recordati S.p.A. - Ribomic Inc. - Virobay Inc. - WEX Pharmaceuticals Inc. - Winston Pharmaceuticals, Inc. - Zynerba Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/3t...ancer_pain
BDSI: 2.23 (-0.04), PFE: 33.76 (-0.21), AMGN: 144.55 (-1.90), ZYNE: 7.17 (-0.48), NKTR: 13.61 (-0.77), AZN: 27.87 (+0.01), VBAY: (), PTIE: 1.98 (-0.05)

Crohn's Disease - Pipeline Review, H1 2015
M2 - Fri Sep 11, 4:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lccxr6/crohns_disease) has announced the addition of the "Crohn's Disease - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Crohn's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Crohn's Disease and special features on late-stage and discontinued projects. the report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from the proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by the team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned Partial list of the 70 companies mentioned in this comprehensive report: - 4SC - AB Science - Baliopharm - BIOCAD - Calypso Biotech - Celgene - Daiichi Sankyo - DBV Technologies - Effimune - Eisai - Farmacija d.o.o. Tuzla - Ferring International Center - Galapagos - Genentech - iCo Therapeutics - Idera Pharmaceuticals - Johnson & Johnson - Kyorin Pharmaceutical - Mabion - Mesoblast - Neovacs - Oncobiologics - Oncodesign - Pfenex - Pfizer - Qu Biologics - Receptos - Sandoz International - Selexys Pharmaceuticals - Takeda Pharmaceutical Company - Teva Pharmaceutical Industries - Virobay - Winston Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/lc...ns_disease
JNJ: 116.14 (+0.51), IDRA: 1.39 (-0.09), TEVA: 48.44 (-1.57), CELGZ: 1.54 (+0.12)

Cancer Pain Therapeutics Pipeline Review, H1 2015 - 28 Companies & 34 Drug Profiles
M2 - Fri Jul 31, 8:47AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5sbhbp/cancer_pain) has announced the addition of the "Cancer Pain - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cancer Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - Amorsa Therapeutics Inc. - AngioChem Inc. - Aphios Corporation - AstraZeneca Plc - BCN Peptides, S.A. - Benitec Biopharma Limited - BioDelivery Sciences International, Inc. - ChironWells GmbH - Daiichi Sankyo Company, Limited - Grunenthal GmbH - GW Pharmaceuticals Plc - Immupharma Plc - IntelGenx Corp. - Kolon Life Science, Inc. - Nektar Therapeutics - Neurocentrx Pharma Ltd. - Nippon Kayaku Co., Ltd. - Northern Light Pharmaceuticals AB - Orion Oyj - Pain Therapeutics, Inc. - Pfizer Inc. - Pharmaleads - Recordati S.p.A. - Sorrento Therapeutics, Inc. - Virobay Inc. - Winston Pharmaceuticals, Inc. - Zynerba Pharmaceuticals, Inc. Drug Profiles - AMS-410 ER12 - ANG-2002 - BBI-11008 - calpastatin - cebranopadol - crotalphine - DD-04107 - dexmedetomidine hydrochloride - dronabinol - Drug for Cancer Neuropathic Pain - fentanyl - fentanyl citrate - fulranumab - HS-198 - hydromorphone hydrochloride - INT-0028 - IPP-102199 - ketamine hydrochloride ER - KLS-2010 - methadone hydrochloride - nabiximols - Nervarna - NKTR-192 - Peptide to Block Voltage-Dependent N-Type Calcium Channel for Cancer Pain and Fibromyalgia - PGN-202 - PL-265 - Q-201 - QX-314 - resiniferatoxin - saracatinib difumarate - Small Molecule 1 to Block Sodium Channels for Cancer Pain and Epilepsy - Small Molecule 2 to Block Sodium Channels for Cancer Pain and Epilepsy - Small Molecule 3 to Block Sodium Channels for Cancer Pain and Epilepsy - Small Molecule to Antagonize Chemokine Receptor for Cancer Pain For more information visit http://www.researchandmarkets.com/research/5s...ancer_pain
BDSI: 2.23 (-0.04), PFE: 33.76 (-0.21), AMGN: 144.55 (-1.90), SRNE: 5.46 (-0.16), ZYNE: 7.17 (-0.48), NKTR: 13.61 (-0.77), AZN: 27.87 (+0.01), VBAY: (), PTIE: 1.98 (-0.05)

Postherpetic Neuralgia - Pipeline Review, H1 2015
M2 - Thu Jun 11, 4:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hg24hw/postherpetic) has announced the addition of the "Postherpetic Neuralgia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Postherpetic Neuralgia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Postherpetic Neuralgia and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned - Aestus Therapeutics - Allergan - Arcion Therapeutics - Astellas Pharma - Daewoong Pharmaceutical - Daiichi Sankyo - Immune Pharmaceuticals - Intellipharmaceutics International - Merck & Co. - NeurAxon - Nuvo Research - Pfizer - Phosphagenics - Purdue Pharma - Relmada Therapeutics - Scilex Pharmaceuticals - Spinifex Pharmaceuticals - Teva Pharmaceutical Industries - Winston Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/hg...stherpetic
AGN: 217.74 (-7.98), IPCI: 1.50 (-0.06), MRK: 55.43 (-0.45), TEVA: 48.44 (-1.57), IMNP: 0.36 (-0.02)

Global Osteoarthritis Market 2015-2019 - Increased Competition in the Market
M2 - Fri Apr 10, 8:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7rntn4/global) has announced the addition of the "Global Osteoarthritis Market 2015-2019" report to their offering. The Global OA market to grow at a CAGR of 8.55 percent over the period 2014-2019. OA is a condition in which the cartilage, a material that cushions the joints, breaks down. This leads to stiffness, inflammation, pain, and loss of joint movement. The exact etiology of OA is not fully understood. Obesity, overuse of the joint, weak thigh muscles, aging, and genetics are some of the common risk factors of OA; OA symptoms usually develop progressively. At first, there may be stiffness that appears to be more a niggle than a medical concern. Treatment is given depending on the affected joint, including the hand, wrist, neck, back, knee, and hip, and involves medication and exercise. This report covers the present scenario and the growth prospects of the Global OA market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of drugs used in the symptomatic treatment and therapeutics of OA that are available in the market. The market can be divided into three segments: Anti-inflammatories, Pain Relievers, and Drugs to Restore Articular Cartilage. The presence of several large and small pharmaceutical companies has resulted in intense competition. Many different classes of drugs, such as NSAIDs, simple analgesics, corticosteroids, and opioids that provide effective relief from discomfort in the early-to-mid stages of osteoarthritis are present in the market. According to the report, certain cellular processes that take place during aging in the human body might contribute to the development of osteoarthritis in some people. As a person ages, the water content of the cartilage increases and the protein makeup of the cartilage degenerates. Thus, an increase in the elderly population drives the market growth. Further, the report states that many patients do not undergo treatment as they are unaware of the disease and its symptoms. In addition, many others avoid drug therapies owing to their side effects, take medications irregularly, or stop consuming them altogether. Key Vendors - Abbott Laboratories - Johnson & Johnson - Novartis - Pfizer Other Prominent Vendors - Abiogen Pharma - Ampio pharmaceuticals - BioDelivery Sciences International - CrystalGenomics - Daiichi Sankyo - Eli Lilly - Horizon Pharma - Iroko Pharmaceuticals - Merck - Nuvo Research - Regeneus - Sanofi - SantoSolve - Smith & Nephew - Winston Pharmaceuticals Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Disease Overview - Market Landscape - Osteoarthritis Pipeline Assessment - Market Segmentation by Drug Class - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/7rntn4/global
BDSI: 2.23 (-0.04), SNN: 31.30 (-1.32), JNJ: 116.14 (+0.51), ABT: 36.88 (-1.03), MRK: 55.43 (-0.45), HZNP: 15.01 (-1.24), LLY: 74.26 (-0.07), NVS: 77.33 (+0.23)

Cancer Pain - Pipeline Review, H1 2014
M2 - Thu Dec 18, 4:20AM CST
Research and Markets (http://www.researchandmarkets.com/research/xthht4/cancer_pain) has announced the addition of the "Cancer Pain - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cancer Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Pain and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cancer Pain - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cancer Pain pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amgen - AstraZeneca - BioDelivery Sciences International - Nektar Therapeutics - Daiichi Sankyo Company - Egalet Corporation - Aphios Corporation - AcelRx Pharmaceuticals - Nippon Kayaku - Nippon Shinyaku - Orion - Pfizer - Zeria Pharmaceutical - GW Pharmaceuticals - IntelGenx - Benitec Biopharma - Kolon Life Science - Teikoku Seiyaku - BioAlliance Pharma - tesa Labtec - Colby Pharmaceutical - Grunenthal - AngioChem - WEX Pharmaceuticals - Virobay - QRxPharma - Winston Pharmaceuticals - Encore Therapeutics - Afferent Pharmaceuticals - Relevare Pharmaceuticals - Northern Light Pharmaceutical For more information visit http://www.researchandmarkets.com/research/xt...ancer_pain
BDSI: 2.23 (-0.04), ACRX: 2.50 (-0.07), EGLT: 4.42 (-0.33), AMGN: 144.55 (-1.90), NKTR: 13.61 (-0.77)

Cancer Pain Therapeutics Pipeline Report 2014 - 30 Companies & 43 Drug Profiles
M2 - Thu Nov 06, 4:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/9s5fww/cancer_pain) has announced the addition of the "Cancer Pain - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cancer Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - AstraZeneca PLC - BioDelivery Sciences International, Inc. - Nektar Therapeutics - Daiichi Sankyo Company, Limited - Egalet Corporation - Aphios Corporation - Nippon Kayaku Co., Ltd. - Nippon Shinyaku Co., Ltd. - Orion Oyj - Pfizer Inc. - Zeria Pharmaceutical Co Ltd - GW Pharmaceuticals plc - IntelGenx Corp. - Benitec Biopharma Limited - Kolon Life Science, Inc. - Teikoku Seiyaku Co., Ltd. - Aoxing Pharmaceutical Company, Inc - BCN Peptides, S.A. - Grunenthal GmbH - AngioChem Inc. - WEX Pharmaceuticals Inc. - Virobay Inc. - Dimerix Bioscience Pty Ltd - Winston Pharmaceuticals, Inc. - Encore Therapeutics Inc. - Sorrento Therapeutics, Inc. - Afferent Pharmaceuticals, Inc. - ChironWells GmbH - Northern Light Pharmaceuticals AB For more information visit http://www.researchandmarkets.com/research/9s...ancer_pain
BDSI: 2.23 (-0.04), PFE: 33.76 (-0.21), AMGN: 144.55 (-1.90), AXN: 0.62 (unch), SRNE: 5.46 (-0.16), NKTR: 13.61 (-0.77), EGLT: 4.42 (-0.33), AZN: 27.87 (+0.01), VBAY: ()

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 232

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
Kinross Lawsuit Puts Round Mountain Claims Under Fire

Updated Category News Views 128

A mine can swallow a rosy forecast faster than any spreadsheet admits. That is the ugly center of the proposed securities class action involving Kinross Gold: not merely that production guidance came down, but the allegation that investors were sold too much confidence before the operational reality at Round Mountain Phase S surfaced. NYSE:KGC dropped from $27.62 on...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 187

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 217

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
WaterField’s Nova Case Bets on Better Handheld Carry

Updated Category News Views 302

Tiny handhelds have spawned a surprisingly fussy luggage problem: protection without the clown-show aesthetic. WaterField Designs is taking a clean swing at that with a custom case for the Retroid Pocket Nova, a sleeve-like carrier built around the device rather than some generic pouch that leaves everything rattling around inside. This is not a market-moving corporate...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 183

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 119

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 154

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 169

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 187

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading

Top 5 Most Recently Viewed Articles

Community Engagement Takes Center Stage at SAS Championship

Updated Category News Views 196

Community Engagement Takes Center Stage at SAS Championship Community initiative supports local teachers, sparks student interest in technology Teachers often face financial challenges covering classroom needs, especially in STEM (science, technology, engineering, and math) education, which is critical for preparing students for a tech-driven future. To alleviate this,...

Continue Reading
Explore Yaber's Next-Gen Projectors Unveiled at CES 2025

Updated Category News Views 305

Innovative Projectors Unveiled by Yaber at CES 2025 Yaber, renowned for its cutting-edge entertainment projectors, revealed its latest models at the CES 2025 event. Among these, the K300s, L2 Plus, and T2 Series stand out, showcasing incredible advancements in home entertainment technology. These projectors are designed to elevate the viewing experience, whether you're...

Continue Reading
Important Update for UroGen Pharma Investors Ahead of Deadline

Updated Category News Views 188

UroGen Pharma Investors: Key Deadline Approaching Attention UroGen Pharma Ltd. investors! The clock is ticking on an important opportunity that you won't want to miss. The class action lawsuit involving UroGen Pharma (URGN) has reached a crucial stage and if you've been affected, now is the time to act. The deadline for an essential step in the lawsuit is coming up on...

Continue Reading
Enhancing Workplace Safety with Voxel's Innovative Impact Boards

Updated Category News Views 121

Revolutionizing Workplace Safety with AI Insights In today's fast-paced work environment, ensuring safety and operational efficiency is paramount. Voxel, an Applied AI company dedicated to transforming workplace safety, has launched its latest innovation: the Impact Boards. These boards are designed to provide tailored, shift-specific safety insights that enable teams to...

Continue Reading
First Quantum Minerals Expands Senior Notes Offering Leadership

Updated Category News Views 112

First Quantum Minerals Expands Senior Notes Offering In a significant development, First Quantum Minerals Ltd. (TSX: FM) has announced a remarkable $1 billion offering of senior notes, demonstrating its strong standing in the mining industry. The company has increased the original offering amount from $750 million to $1 billion, clearly indicating investor confidence and...

Continue Reading